Aims: The respective roles of oral anticoagulation or antiplatelet therapy following transcatheter aortic valve implantation (TAVI) remain debated. ATLANTIS is an international, randomized, open-label, superiority trial comparing apixaban to the standard of care.
Methods And Results: After successful TAVI, 1500 patients were randomized (1:1) to receive apixaban 5 mg (2.